Kestra Medical Technologies, Lt (KMTS) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $19.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and... Read more
Sell if holding. Engine safety override at $19.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 69d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Kestra Medical Technologies, Lt
Latest news
- Goldman Sachs Maintains Neutral on Kestra Medical Techs, Lowers Price Target to $17 — benzinga Apr 9, 2026 neutral
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -173.0%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $19.51: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 1.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $18.43. Score 5.3/10, moderate confidence.
Take-profit target: $24.11 (+23.1% upside). Prior stop was $18.43. Stop-loss: $18.43.
Quality below floor (3.5 < 4.0).
Kestra Medical Technologies, Lt trades at a P/E of N/A (forward -9.2). TrendMatrix value score: 4.9/10. Verdict: Sell.
13 analysts cover KMTS with a consensus score of 4.3/5. Average price target: $28.
What does Kestra Medical Technologies, Lt do?Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on...
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes. The company was founded in 2014 and is based in Kirkland, Washington.